Skip to main content
Smart Investors Daily
KY

NASDAQ · KYTX

Kyverna Therapeutics, Inc.

Healthcare · Biotechnology

$4.76

Down-$0.29 (-5.74%)

Updated Nov 17, 2026, 2:32 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
364.57M
P/E ratio
-2.27
Dividend yield
0.00%
52-week range
$4.50 – $11.62
Volume
767.38K
Avg. volume
697.76K

Price performance · KYTX

KYTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

KYTX closed at $4.76 after 21 trading sessions, down 18.35% for the selected period.

Last close
$4.76
Period change
-18.35%
Period low
$4.61
Period high
$6.04
Daily close
View OHLC price history
KYTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$4.95$5.07$4.735$4.76767.38K
Nov 13, 2026$5.54$5.54$4.82$5.05834.5K
Nov 12, 2026$5.29$5.29$4.765$5.031.2M
Nov 11, 2026$5.12$5.23$5.0182$5.12507.3K
Nov 10, 2026$5.14$5.28$4.995$5.08472.27K
Nov 9, 2026$4.91$5.24$4.80$5.17831.4K
Nov 6, 2026$4.68$5.00$4.65$4.88885.57K
Nov 5, 2026$5.11$5.11$4.495$4.611.43M
Nov 4, 2026$5.30$5.46$5.02$5.16974.15K
Nov 3, 2026$5.28$5.48$5.12$5.16704.67K
Nov 2, 2026$5.70$5.84$5.0925$5.22822.31K
Oct 30, 2026$5.74$5.87$5.55$5.67640.17K
Oct 29, 2026$5.91$6.12$5.83$5.85854.64K
Oct 28, 2026$5.58$5.935$5.56$5.89995.41K
Oct 27, 2026$5.24$5.67$5.16$5.63916.66K
Oct 26, 2026$5.35$5.41$5.18$5.27810.11K
Oct 23, 2026$5.68$5.68$5.36$5.39827.75K
Oct 22, 2026$5.825$5.985$5.67$5.73519.39K
Oct 21, 2026$6.15$6.30$5.80$5.84829.52K
Oct 20, 2026$5.83$6.20$5.80$6.04766.31K
Oct 19, 2026$5.71$5.94$5.67$5.83837.71K

Latest KYTX news

The latest Smart Investors Daily articles mentioning KYTX.

KYTX research

Overview

Company profile and research snapshot.

Company profile

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.50
Implied upside
—
Analysts
—
KYTX recent ratings
DateFirmRatingTarget
Jun 3, 2026HC Wainwright & Co.Buy—
May 15, 2026HC Wainwright & Co.Buy—
May 13, 2026JP MorganOverweight—
Apr 23, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease Initially presented at AAN, the primary analysis measured at 16 weeks demonstrated statistically significant improvements across all primary and secondary endpoints, including mobility and disability, with patients no longer requiring chronic immunotherapi

Yahoo · Nov 5, 2026

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at i

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.